CASI Pharmaceuticals Inc (NASDAQ:CASI) — Market Cap & Net Worth
Market Cap & Net Worth: CASI Pharmaceuticals Inc (CASI)
CASI Pharmaceuticals Inc (NASDAQ:CASI) has a market capitalization of $4.26 Million ($4.26 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28986 globally and #5927 in its home market, demonstrating a -68.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CASI Pharmaceuticals Inc's stock price $0.24 by its total outstanding shares 20548273 (20.55 Million). Also see CASI current and non-current assets for a full breakdown of the balance sheet.
CASI Pharmaceuticals Inc Market Cap History: 2015 to 2026
CASI Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $197.26 Million to $4.99 Million (-32.56% CAGR). Also see cash efficiency ratio of CASI Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Index Memberships
CASI Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #837 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2691 of 3165 |
Weight: CASI Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CASI Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CASI Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check CASI share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.04x
CASI Pharmaceuticals Inc's market cap is 2.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $197.26 Million | $47.71K | -$7.21 Million | 4134.46x | N/A |
| 2019 | $634.94 Million | $4.13 Million | -$45.36 Million | 153.70x | N/A |
| 2020 | $606.17 Million | $15.14 Million | -$48.29 Million | 40.04x | N/A |
| 2021 | $164.39 Million | $30.17 Million | -$36.65 Million | 5.45x | N/A |
| 2022 | $36.78 Million | $43.11 Million | -$41.01 Million | 0.85x | N/A |
| 2023 | $147.13 Million | $33.88 Million | -$26.94 Million | 4.34x | N/A |
| 2024 | $58.15 Million | $28.54 Million | -$39.26 Million | 2.04x | N/A |
Competitor Companies of CASI by Market Capitalization
Companies near CASI Pharmaceuticals Inc in the global market cap rankings as of September 18, 2026. Review CASI Pharmaceuticals Inc (CASI) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CASI Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
CASI Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, CASI Pharmaceuticals Inc's market cap moved from $197.26 Million to $ 4.99 Million, with a yearly change of -32.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.99 Million | -71.42% |
| 2025 | $17.47 Million | -69.96% |
| 2024 | $58.15 Million | -60.47% |
| 2023 | $147.13 Million | +300.00% |
| 2022 | $36.78 Million | -77.62% |
| 2021 | $164.39 Million | -72.88% |
| 2020 | $606.17 Million | -4.53% |
| 2019 | $634.94 Million | -23.13% |
| 2018 | $826.04 Million | +23.69% |
| 2017 | $667.82 Million | +182.61% |
| 2016 | $236.31 Million | +19.79% |
| 2015 | $197.26 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of CASI Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.26 Million USD |
| MoneyControl | $4.26 Million USD |
| MarketWatch | $4.26 Million USD |
| marketcap.company | $4.26 Million USD |
| Reuters | $4.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. Th… Read more